Advertisement

Topics

ESMO 2017: New data confirms superiority of docetaxel based triplet therapy in gastric cancer

06:31 EDT 8 Sep 2017 | ecancermedicalscience

The superiority of docetaxel based triplet therapy over standard care in patients with resectable oesophago-gastric cancer has been confirmed in late-breaking results from the FLOT4 trial presented at the ESMO 2017 Congress in Madrid.  Survival in...

Original Article: ESMO 2017: New data confirms superiority of docetaxel based triplet therapy in gastric cancer

NEXT ARTICLE

More From BioPortfolio on "ESMO 2017: New data confirms superiority of docetaxel based triplet therapy in gastric cancer"

Quick Search
Advertisement